What Liquid Biosciences does

Liquid Biosciences is a privately held biotechnology analytics company founded circa 2015 by Patrick Lilley (CEO) and Roland Muduryan (CFO/COO), headquartered in Aliso Viejo, California. The company operates a proprietary bio-analytics platform that applies advanced AI and machine learning to structured biological and clinical data to discover novel biomarkers, rescue failed drug candidates, and accelerate drug development across more than 60 disease areas including oncology, neurology, and chronic disease management. According to company disclosures, the platform has supported over 300 healthcare projects and has been used to discover hundreds of novel biomarkers, with a stated 90%+ sensitivity/specificity on autism spectrum disorder (ASD) biomarker work and a claimed 100% project success rate.

The company generates revenue through project-based bio-analytics services sold via direct enterprise engagement to biopharma companies, diagnostic firms, clinical research organizations, and academic and research institutions, with a reported client base of 35 leading institutions worldwide. Its go-to-market is minimal-public-marketing, relationship-driven B2B sales initiated through its website contact form, with no public pricing or partner channel disclosed. The product is delivered as a single unified platform rather than a portfolio of discrete tools, and the business is supported by a small team of 11-50 employees with deep technical leadership concentrated in its two co-founders.

Name

Liquid Biosciences

Legal name

Liquid Biosciences

Website

https://liquidbiosciences.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Liquid Biosciences is a private biotech analytics company that uses an AI-driven bio-analytics platform to discover biomarkers, rescue failed drugs, and accelerate development across 60+ diseases for 35 biopharma, diagnostic, CRO, and academic clients.

Ownership category

akta.pro rank

Product category

Bioinformatics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Translational Medicine & Biomarkers (HLAIALAF), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)

Keywords

• Biomarker discovery
• Bio-analytics platform
• Drug development services
• AI bioinformatics
• Clinical research analytics

Headquarters

HQ city

Orange

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Bio-analytics Services: Project-based bio-analytics services for biopharma, diagnostic, and clinical research organizations involving biomarker discovery, drug rescue, and development acceleration. Services are provided to 35 institutional clients globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Liquid Biosciences provides project-based bio-analytics services powered by a proprietary AI-driven platform that discovers novel biomarkers, rescues failed drugs, and accelerates drug development. The platform has been applied across more than 60 diseases and over 300 completed projects for 35 biopharma, diagnostic, clinical research, and academic institution clients. Services cover biomarker identification, drug rescue, clinical trial analytics, and translational research support.

Product overview

Liquid Biosciences offers a single unified product — its proprietary bio-analytics platform — which serves as the core technology for all service delivery. The platform leverages advanced AI to process biological and clinical data for biomarker discovery, drug rescue, and drug development acceleration across oncology, neurology, and chronic disease management. The company operates on a project-based model, serving 35 biopharma, diagnostic, clinical research, and academic institution clients globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Liquid Biosciences Bio-Analytics Platform A proprietary bio-analytics platform that uses advanced AI and machine learning to analyze biological data, discover novel biomarkers, rescue failed drugs, and accelerate drug development across more than 60 diseases. Sold via project-based professional services engagements to biopharma, diagnostic, clinical research, and academic institution clients; has supported over 300 healthcare projects for 35 institutional clients globally.
• Biomarker Discovery Services Project-based biomarker discovery engagements that identify novel biomarkers across multiple disease areas for biopharma, diagnostic, and clinical research clients. Demonstrated 90%+ sensitivity and specificity in autism spectrum disorder biomarker discovery and used to support diagnostic test development and clinical research programs.
• Drug Rescue and Drug Development Acceleration Services Project-based services that apply the bio-analytics platform to rescue failed drug candidates by identifying new therapeutic targets and biomarkers, and to accelerate development of new therapeutics. Targeted at biopharma clients facing high drug failure rates and lengthy development timelines.

Quantifiable outcome

• Over 90% accuracy in sensitivity and specificity for biomarker discovery (ASD case study)
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

One partnership is on record.

• Ignite BiomedicalcoreStrategic or Co-development Partner · 4 November 2025Joint discovery of biomarkers for autism spectrum disorder (ASD) diagnosis and treatment. The collaboration achieved over 90% accuracy in sensitivity and specificity, enabling earlier diagnosis and potential development of therapeutics for ASD.

Scale indicators5 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Berg Health (formerly Berg Pharma): AI-driven biomarker discovery and drug development company that uses proprietary multi-omics analytics to identify novel targets and rescue failed compounds. Closely comparable in business model (platform + services), therapeutic breadth, and emphasis on drug rescue — a near-direct analog to Liquid Biosciences.
• Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning to identify targets and accelerate development. Comparable as a peer AI drug-discovery platform; larger scale and well-funded, but operates in the same biomarker-and-discovery category.
• Insitro: Machine-learning-driven drug discovery company combining induced pluripotent stem cell biology with ML models for target identification and biomarker discovery. Directly comparable on the AI-for-drug-and-biomarker-discovery axis, though operating at larger scale with major pharma partnerships.
• Exscientia: AI-driven precision medicine and drug discovery company that uses machine learning to design and prioritize drug candidates. Direct competitor in AI drug discovery with a broader product orientation (small molecule design) but overlapping client base of biopharma partners.
• InSilico Medicine: AI-driven drug discovery and biomarker company with end-to-end platforms for target identification, molecule generation, and clinical prediction. Comparable as an AI drug-discovery peer with a services-plus-platform model that has scaled into pharma partnerships.
• Lantern Pharma: AI-driven oncology drug development company using its RADR platform to rescue and accelerate oncology drug candidates. Closely comparable in the drug rescue and AI biomarker positioning, particularly within oncology.
• Standigm: AI-driven drug discovery company applying deep learning to identify novel targets and optimize leads across multiple therapeutic areas. Comparable as an AI drug-discovery platform peer with similar pharma partnership GTM.
• XtalPi: AI + quantum physics-driven drug discovery company combining computation with wet-lab validation to accelerate candidate identification. Comparable as a tech-forward AI drug-discovery peer, though more capital-intensive and operating at larger scale.

Broad incumbents

• Schrödinger: Computational chemistry and molecular simulation platform serving pharma R&D broadly. Overlaps with Liquid Biosciences on AI/ML for drug discovery and biomarker insights, but operates a much broader software platform serving many therapeutic areas.
• Ginkgo Bioworks: Synthetic biology platform company with cell engineering and biosecurity capabilities that uses data/ML at scale. Tangentially comparable as a broader biotech platform using AI/ML and serving enterprise customers, but oriented around synthetic biology rather than biomarker discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/liquid-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liquid Biosciences